AmorChem launches SemaThera with $1 mln in seed funding
AmorChem has launched SemaThera Inc, a Montréal biotechnology company focused on the development of novel SEMA 3A TRAP inhibitors for the treatment of ocular diseases, such as diabetic macular edema. The startup was also provided with $1 million in seed funding. Maxime Ranger will be appointed the company's CEO, while Dr. Przemyslaw Sapieha, who researched the SEMA 3A technology, will be appointed CSO. SemaThera is one of three companies recently spun out by AmorChem, a fund managed by Canadian life sciences venture capital firm GeneChem. Another, Corbin Therapeutics Inc, was also unveiled this week.
12 January 2017•5 mins read
